FREMONT, CA - February 26, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, announces a new strategy with its joint venture partner, BioLite Japan. The parties aim to accelerate the growth of Japan's biotechnology industry by facilitating access to Taiwan’s capital market and leveraging cutting-edge AI resources for advanced development.
Empowering Japan's Biotech Startups
Japan’s biotech industry is valued at over $120 billion, with over 3,000 biotech startups seeking opportunities to expand globally. [1] BioLite Japan seeks to identify high-potential Japanese biotech innovations and guide them through the complex process of international expansion. This includes helping them to secure capital, navigate regulatory frameworks, and form strategic partnerships across Asia and the United States.
Taiwan: A Gateway to Growth
Taiwan’s biomedical sector, valued at $23.5 billion[2], offers a strong foundation for biotech companies looking to expand. BioLite Japan will assist Japanese biotech firms trying to enter Taiwan’s thriving biomedical landscape, including the prestigious Hsinchu Biomedical Park. Taiwan’s AI-driven healthcare sector, which is growing at 15% annually, will be instrumental in accelerating drug discovery and biotech innovation.
Silicon Valley: The Manufacturing Hub
To further strengthen the value chain, ABVC will provide manufacturing support through its wholly owned subsidiary, BioKey, Inc., located in Silicon Valley, California. The GMP-certified facility will serve as the primary production base, to help ensure high-quality biotech manufacturing. The global biotech contract manufacturing market, currently estimated at $150 billion, presents a major opportunity for companies leveraging state-of-the-art U.S.-based facilities.[3]
“This strategic plan is expected to help expand ABVC’s global footprint,” said Uttam Patil, Ph.D., Chief Executive Officer of ABVC. “By bridging Japan’s cutting-edge biotech innovations with Taiwan’s AI resources and our manufacturing strength in Silicon Valley, we believe we will establish a seamless ecosystem for biotech advancement. "Our experience navigating the FDA regulatory landscape positions us as a strong partner in the joint venture. With a proven track record of advancing clinical-stage programs through regulatory approvals, we bring valuable expertise to accelerate innovative therapies' development and commercialization. This collaboration will leverage our deep regulatory insights to help provide streamlined and efficient pathway to market success."
Toru Jay Seo, Ph.D., CEO of BioLite Japan and former Worldwide Business Development, Chief Business Officer of Pfizer Inc., echoed this enthusiasm:
“We are excited to collaborate with ABVC to provide Japanese biotech startups with a clear pathway to international success. By leveraging Taiwan’s capital market and AI-driven technologies alongside BioKey’s manufacturing capabilities in Silicon Valley, we believe we can build a comprehensive value chain that accelerates innovation and global market entry for Japan’s most promising biotech companies. Through this collaboration and expertise of the parties, Biolite Japan will execute an initiative to promote JP biotechs for global expansion.”
Looking Ahead
Through this strategic alliance, ABVC and BioLite Japan aim to position biotech startups in Japan for success in international markets. We believe the partnership offers a comprehensive pathway for biotech innovation to thrive globally.
For more information, please visit www.abvcpharma.com and
For more information about ABVC and its subsidiaries, stay updated on the latest updates or visit https://abvcpharma.com. Visit https://biolite-japan.com for more information on BioLite Japan. ABVC urges its shareholders to sign up on the Company's website for the latest news alerts; visit https://abvcpharma.com/?page_id=17707
About ABVC BioPharma & Its Industry
ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. For its drug products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. The Company's network of research institutions includes Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the Company intends to conduct global clinical trials through Phase III.
Forward-Looking Statements
This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential," or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. None of the outcomes expressed herein are guaranteed. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company's securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
Contact:
Dr. Uttam Patil
Email: uttam@ambrivis.com
View the original release on www.newmediawire.com
